NASDAQ:RXII - RXi Pharmaceuticals Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding RXi Pharmaceuticals Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Today's Range N/A50-Day Range$0.36MA: $0.42▼$0.5052-Week Range N/AVolume190,336 shsAverage Volume1.73 million shsMarket Capitalization$41.39 millionP/E RatioN/ADividend YieldN/ABeta2.07 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RXII Previous Symbol CUSIPN/A CIK1533040 Webhttp://www.rxipharma.com/ Phone508-767-3861Debt Debt-to-Equity RatioN/A Current Ratio1.77 Quick Ratio1.77Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$10,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.77 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($4.20) Net Income$-12,450,000.00 Net Margins-4,990.20% Return on Equity-412.15% Return on Assets-179.54%Miscellaneous EmployeesN/A Outstanding Shares4,380,000Market Cap$41.39 million Next Earnings DateN/A OptionableNot Optionable Receive RXII News and Ratings via Email Sign-up to receive the latest news and ratings for RXII and its competitors with MarketBeat's FREE daily newsletter. RXi Pharmaceuticals (NASDAQ:RXII) Frequently Asked Questions What is RXi Pharmaceuticals' stock symbol? RXi Pharmaceuticals trades on the NASDAQ under the ticker symbol "RXII." When did RXi Pharmaceuticals' stock split? How did RXi Pharmaceuticals' stock split work? RXi Pharmaceuticals's stock reverse split on the morning of Monday, January 8th 2018. The 1-10 reverse split was announced on Friday, January 5th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 5th 2018. An investor that had 100 shares of RXi Pharmaceuticals stock prior to the reverse split would have 10 shares after the split. How were RXi Pharmaceuticals' earnings last quarter? RXi Pharmaceuticals Corp (NASDAQ:RXII) announced its quarterly earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.46) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.62) by $0.16. The biotechnology company had revenue of $0.06 million for the quarter, compared to analysts' expectations of $0.02 million. RXi Pharmaceuticals had a negative return on equity of 412.15% and a negative net margin of 4,990.20%. View RXi Pharmaceuticals' Earnings History. Has RXi Pharmaceuticals been receiving favorable news coverage? Media headlines about RXII stock have trended extremely negative on Friday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. RXi Pharmaceuticals earned a daily sentiment score of -4.4 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for RXi Pharmaceuticals. Who are some of RXi Pharmaceuticals' key competitors? Some companies that are related to RXi Pharmaceuticals include Scpharmaceuticals (SCPH), Fortress Biotech (FBIO), Kezar Life Sciences (KZR), Akorn (AKRX), GlycoMimetics (GLYC), Genprex (GNPX), Cerecor (CERC), Ovid Therapeutics (OVID), Selecta Biosciences (SELB), ContraFect (CFRX), Paratek Pharmaceuticals (PRTK), Avenue Therapeutics (ATXI), Marinus Pharmaceuticals (MRNS), Tyme Technologies (TYME) and Strongbridge Biopharma (SBBP). What other stocks do shareholders of RXi Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other RXi Pharmaceuticals investors own include Rigel Pharmaceuticals (RIGL), Idera Pharmaceuticals (IDRA), Novavax (NVAX), Auris Medical (EARS), Endologix (ELGX), Synergy Pharmaceuticals (SGYP), Protalix Biotherapeutics (PLX), Anavex Life Sciences (AVXL), Micron Technology (MU) and Rexahn Pharmaceuticals (REXN). Who are RXi Pharmaceuticals' key executives? RXi Pharmaceuticals' management team includes the folowing people: Dr. Geert Cauwenbergh, Pres, CEO, Acting CFO & Director (Age 64)Dr. Gerrit Dispersyn Dr. Med. Sc, Chief Devel. Officer (Age 43)Ms. Caitlin Kontulis, Sr. Director of Fin. & Sec. (Age 32)Dr. Karen Bulock, Former VP of Research How big of a company is RXi Pharmaceuticals? RXi Pharmaceuticals has a market capitalization of $0.00 and generates $10,000.00 in revenue each year. The biotechnology company earns $-12,450,000.00 in net income (profit) each year or ($4.20) on an earnings per share basis. View Additional Information About RXi Pharmaceuticals. What is RXi Pharmaceuticals' official website? The official website for RXi Pharmaceuticals is http://www.rxipharma.com/. How can I contact RXi Pharmaceuticals? RXi Pharmaceuticals' mailing address is 257 SIMARANO DRIVE SUITE 101, MARLBOROUGH MA, 01752. The biotechnology company can be reached via phone at 508-767-3861 or via email at [email protected] MarketBeat Community Rating for RXi Pharmaceuticals (NASDAQ RXII)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 189 (Vote Outperform)Underperform Votes: 180 (Vote Underperform)Total Votes: 369MarketBeat's community ratings are surveys of what our community members think about RXi Pharmaceuticals and other stocks. Vote "Outperform" if you believe RXII will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RXII will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/28/2020 by MarketBeat.com StaffFeatured Article: What is the Coverage Ratio?
